ストックスクリーナーアプリを入手
9.58
36.86%
2.58
アフターアワーズ：
9.29
-0.29
-3.03%
前日終値:
$7.00
開ける：
$7
24時間の取引高:
109.68K
Relative Volume:
20.68
時価総額：
$254.03M
収益：
-
当期純損益:
-
株価収益率:
-
EPS:
-
ネットキャッシュフロー:
-
1週間 パフォーマンス:
-20.17%
1か月 パフォーマンス:
+0.00%
6か月 パフォーマンス:
+0.00%
1年 パフォーマンス:
+0.00%
1日の値動き範囲:
$6.10
$10.44
1週間の範囲:
$6.10
$21.00
52週間の値動き範囲:
$6.10
$21.00
Neonc Technologies Holdings Inc Stock (NTHI) Company Profile
NTHI を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
NTHI
Neonc Technologies Holdings Inc
|
9.58 | 254.03M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.01 | 124.29B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
610.64 | 68.39B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
590.06 | 35.99B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
262.16 | 33.93B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
264.32 | 28.47B | 3.81B | -644.79M | -669.77M | -6.24 |
Neonc Technologies Holdings Inc (NTHI) 最新ニュース
Neonc Technologies appoints new accounting firm By Investing.com - Investing.com Canada
Neonc Technologies appoints new accounting firm - Investing.com India
NeOnc Technologies Partners with CBCC for Clinical Expansion - TipRanks
NeOnc Technologies receives RPDD for NEO100 - TipRanks
NeOnc Technologies Holdings: New IPO gets a Rare Pediatric Disease Designation and a 37.92% Jump in the Market - RagingBull
NeOnc Technologies Holdings' Perillyl Alcohol Receives FDA's Rare Pediatric Disease Designation - MarketScreener
NeOnc Falls Despite FDA Nod - Baystreet.ca
NeOnc Technologies Holdings, Inc. Receives Rare Pediatric - GlobeNewswire
Robinhood, Couchbase And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Benzinga
NeOnc Technologies Holdings, Inc. Receives Rare Pediatric Disease Designation for NEO100 in Treatment of Pediatric-Type Diffuse High-Grade Gliomas - Yahoo Finance
NeOnc Technologies Expands Global Clinical Trial Network with CBCC Global Research to Accelerate Study of Brain Cancer Treatments - The Manila Times
NeOnc Technologies Expands Global Clinical Trial Network - GlobeNewswire
NeOnc Technologies Holdings, Inc. Rings the Opening Bell - Nasdaq
NTHI IPO NewsBiotech NeOnc Technologies' share registration declared effective ahead of Nasdaq direct listing - renaissancecapital.com
NeOnc Technologies Holdings Announces Effectiveness of - GlobeNewswire
NeOnc Technologies Holdings Announces Effectiveness of Registration Statement and Anticipated Listing Date of Common Stock on Nasdaq Global Market - Yahoo Finance
NEONC Technologies Holdings, Inc. Appoints Dr. Alan Chiang to its Board of Directors - Yahoo Finance
NeOnc Technologies Holdings, Inc. Appoints Bader Almonawer to Board of Directors - GlobeNewswire
NeOnc Technologies Holdings, Inc. Appoints Dr. Steven L. Giannotta to Board of Directors - Nasdaq
Nasdaq’s opening bell will ring for USC research startup NeOnc - USC Today
Planet TV Studios Airing “New Frontiers” Episode on NeOnc Technologies Holdings, Inc. – Saturday, March 15, - EIN News
Expanding horizons: NeOnc Technologies’ bold vision - The Business Journals
NeOnc Technologies plans to go public through direct listing - AlphaStreet
NeOnc Technologies has another go at a Nasdaq listing - Pharmaphorum
Cancer Drug Co. Revives Bid To Go Public Via Direct Listing - Law360
NeOnc Technologies Receives Pharma Tech Outlook’s Top Drug Delivery Platform Award for 2024 - GlobeNewswire
A Biotech Going Through the Nose to Treat the Brain Plots Alternative Path to Public Markets - MedCity News
NeOnc Technologies Begins Enrollment for Phase 2 Clinical Trial of NEO100-02™ for Patients Afflicted with Meningioma, Marking Second Concurrent Phase 2 Study of Leading CNS Cancer Drug Candidate - GlobeNewswire
NeOnc Initiates Cohort 3 in Phase 1 Clinical Trial of NEO212™, a Patented Novel Hybrid Drug Designed to Deliver ‘Double Punch’ Against Malignant Brain Tumors - BioSpace
NeOnc Technologies Receives FDA Approval to Expand - GlobeNewswire
NeOnc Technologies Completes $18.5 Million Financing, Advances Phase II Clinical Trials for Enhanced Method of Delivering Novel Therapeutics to the Brain Under FDA Fast-Track Status - GlobeNewswire
NeOnc Technologies Holdings: NTHI IPO, Health CarePhase 2 biotech developing intranasal and oral therapies for brain cancer. - renaissancecapital.com
NeOnc Technologies Holdings Receives FDA Authorization to - GlobeNewswire
NeOnc Technologies Appoints Sidra Medicine CEO and Forbes - GlobeNewswire
NeOnc Technologies CEO, Thomas Chen, MD, Ph.D., Awarded American Health Council’s ‘Best in Medicine’ - GlobeNewswire
Neonc Technologies Holdings Inc (NTHI) 財務データ
Neonc Technologies Holdings Inc (NTHI) の財務データはありません。詳細については、他の銘柄を確認してください。
収益
当期純利益
現金流量
EPS
1.23%
1.63%
大文字化:
|
ボリューム (24 時間):